Glucose metabolism in glucose-intolerant older people during chromium supplementation

Jane F. Potter, Philip Levin, Richard A. Anderson, J. Michael Freiberg, Reubin Andres, Dariush Elahi

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

The effects of chromic chloride (CrCl3) administered orally for 12 weeks to five elderly subjects with glucose intolerance were assessed. Pretreatment and posttreatment, the hyperglycemic clamp technique was employed to determine glucose utilization, β-cell sensitivity to glucose, and tissue sensitivity to insulin. In addition, erythrocyte insulin binding was studied. Urinary chromium excretion increased approximately 5 fold indicating good compliance with supplementation. The oral glucose tolerance curves following supplementation were lowered from 60 to 120 minutes but only the 60-minute values were significantly lowered. In agreement with this was significantly increased glucose utilization during the hyperglycemic clamp studies. Tissue sensitivity to insulin, receptor affinity, and total insulin binding were unchanged by supplementation while β-cell sensitivity to glucose increased following supplementation (P < 0.04), and explained the increased glucose utilization. HDL and LDL and total cholesterol levels were slightly lower after chromium supplementation, but no change reached statistical significance. The LDL HDL cholesterol ratio was unchanged. This study shows small but statistically significant effects of CrCl3 on carbohydrate metabolism. The clinical relevance of these effects, that is, their prophylactic or therapeutic significance, remains to be determined.

Original languageEnglish (US)
Pages (from-to)199-204
Number of pages6
JournalMetabolism
Volume34
Issue number3
DOIs
StatePublished - Mar 1985

Fingerprint

Chromium
Glucose
LDL Cholesterol
Insulin
Glucose Intolerance
Insulin Receptor
Carbohydrate Metabolism
Glucose Tolerance Test
HDL Cholesterol
Insulin Resistance
Erythrocytes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Glucose metabolism in glucose-intolerant older people during chromium supplementation. / Potter, Jane F.; Levin, Philip; Anderson, Richard A.; Freiberg, J. Michael; Andres, Reubin; Elahi, Dariush.

In: Metabolism, Vol. 34, No. 3, 03.1985, p. 199-204.

Research output: Contribution to journalArticle

Potter, JF, Levin, P, Anderson, RA, Freiberg, JM, Andres, R & Elahi, D 1985, 'Glucose metabolism in glucose-intolerant older people during chromium supplementation', Metabolism, vol. 34, no. 3, pp. 199-204. https://doi.org/10.1016/0026-0495(85)90001-0
Potter, Jane F. ; Levin, Philip ; Anderson, Richard A. ; Freiberg, J. Michael ; Andres, Reubin ; Elahi, Dariush. / Glucose metabolism in glucose-intolerant older people during chromium supplementation. In: Metabolism. 1985 ; Vol. 34, No. 3. pp. 199-204.
@article{876a20f149ed4ff3a6420d5e9e5eee04,
title = "Glucose metabolism in glucose-intolerant older people during chromium supplementation",
abstract = "The effects of chromic chloride (CrCl3) administered orally for 12 weeks to five elderly subjects with glucose intolerance were assessed. Pretreatment and posttreatment, the hyperglycemic clamp technique was employed to determine glucose utilization, β-cell sensitivity to glucose, and tissue sensitivity to insulin. In addition, erythrocyte insulin binding was studied. Urinary chromium excretion increased approximately 5 fold indicating good compliance with supplementation. The oral glucose tolerance curves following supplementation were lowered from 60 to 120 minutes but only the 60-minute values were significantly lowered. In agreement with this was significantly increased glucose utilization during the hyperglycemic clamp studies. Tissue sensitivity to insulin, receptor affinity, and total insulin binding were unchanged by supplementation while β-cell sensitivity to glucose increased following supplementation (P < 0.04), and explained the increased glucose utilization. HDL and LDL and total cholesterol levels were slightly lower after chromium supplementation, but no change reached statistical significance. The LDL HDL cholesterol ratio was unchanged. This study shows small but statistically significant effects of CrCl3 on carbohydrate metabolism. The clinical relevance of these effects, that is, their prophylactic or therapeutic significance, remains to be determined.",
author = "Potter, {Jane F.} and Philip Levin and Anderson, {Richard A.} and Freiberg, {J. Michael} and Reubin Andres and Dariush Elahi",
year = "1985",
month = "3",
doi = "10.1016/0026-0495(85)90001-0",
language = "English (US)",
volume = "34",
pages = "199--204",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Glucose metabolism in glucose-intolerant older people during chromium supplementation

AU - Potter, Jane F.

AU - Levin, Philip

AU - Anderson, Richard A.

AU - Freiberg, J. Michael

AU - Andres, Reubin

AU - Elahi, Dariush

PY - 1985/3

Y1 - 1985/3

N2 - The effects of chromic chloride (CrCl3) administered orally for 12 weeks to five elderly subjects with glucose intolerance were assessed. Pretreatment and posttreatment, the hyperglycemic clamp technique was employed to determine glucose utilization, β-cell sensitivity to glucose, and tissue sensitivity to insulin. In addition, erythrocyte insulin binding was studied. Urinary chromium excretion increased approximately 5 fold indicating good compliance with supplementation. The oral glucose tolerance curves following supplementation were lowered from 60 to 120 minutes but only the 60-minute values were significantly lowered. In agreement with this was significantly increased glucose utilization during the hyperglycemic clamp studies. Tissue sensitivity to insulin, receptor affinity, and total insulin binding were unchanged by supplementation while β-cell sensitivity to glucose increased following supplementation (P < 0.04), and explained the increased glucose utilization. HDL and LDL and total cholesterol levels were slightly lower after chromium supplementation, but no change reached statistical significance. The LDL HDL cholesterol ratio was unchanged. This study shows small but statistically significant effects of CrCl3 on carbohydrate metabolism. The clinical relevance of these effects, that is, their prophylactic or therapeutic significance, remains to be determined.

AB - The effects of chromic chloride (CrCl3) administered orally for 12 weeks to five elderly subjects with glucose intolerance were assessed. Pretreatment and posttreatment, the hyperglycemic clamp technique was employed to determine glucose utilization, β-cell sensitivity to glucose, and tissue sensitivity to insulin. In addition, erythrocyte insulin binding was studied. Urinary chromium excretion increased approximately 5 fold indicating good compliance with supplementation. The oral glucose tolerance curves following supplementation were lowered from 60 to 120 minutes but only the 60-minute values were significantly lowered. In agreement with this was significantly increased glucose utilization during the hyperglycemic clamp studies. Tissue sensitivity to insulin, receptor affinity, and total insulin binding were unchanged by supplementation while β-cell sensitivity to glucose increased following supplementation (P < 0.04), and explained the increased glucose utilization. HDL and LDL and total cholesterol levels were slightly lower after chromium supplementation, but no change reached statistical significance. The LDL HDL cholesterol ratio was unchanged. This study shows small but statistically significant effects of CrCl3 on carbohydrate metabolism. The clinical relevance of these effects, that is, their prophylactic or therapeutic significance, remains to be determined.

UR - http://www.scopus.com/inward/record.url?scp=0022002965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022002965&partnerID=8YFLogxK

U2 - 10.1016/0026-0495(85)90001-0

DO - 10.1016/0026-0495(85)90001-0

M3 - Article

C2 - 3883094

AN - SCOPUS:0022002965

VL - 34

SP - 199

EP - 204

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 3

ER -